HC Wainwright restated their buy rating on shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) in a research note published on Wednesday morning. They currently have a $10.00 price objective on the stock.

A number of other analysts also recently commented on AUPH. Leerink Swann restated an outperform rating and issued a $7.00 target price on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 6th. Canaccord Genuity set a $10.00 target price on Aurinia Pharmaceuticals and gave the stock a buy rating in a research note on Friday, August 5th. Finally, FBR & Co restated an outperform rating and issued a $9.00 target price on shares of Aurinia Pharmaceuticals in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $7.75.

Aurinia Pharmaceuticals (NASDAQ:AUPH) traded up 33.58% during mid-day trading on Wednesday, reaching $5.41. The company’s stock had a trading volume of 16,739,921 shares. The firm’s 50 day moving average is $2.30 and its 200-day moving average is $2.75. The company’s market cap is $190.90 million. Aurinia Pharmaceuticals has a 12-month low of $1.42 and a 12-month high of $5.69.

A hedge fund recently raised its stake in Aurinia Pharmaceuticals stock. Abingworth LLP boosted its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 479.8% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 512,036 shares of the company’s stock after buying an additional 423,729 shares during the period. Aurinia Pharmaceuticals makes up about 1.5% of Abingworth LLP’s portfolio, making the stock its 16th largest position. Abingworth LLP owned about 1.56% of Aurinia Pharmaceuticals worth $1,388,000 at the end of the most recent reporting period. Institutional investors own 20.04% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

5 Day Chart for NASDAQ:AUPH

Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.